Clinical trial of intravitreal activated Protein C (Anact C®) for central retinal vein occusio
Phase 1
- Conditions
- Central retinal vein occlusion
- Registration Number
- JPRN-UMIN000008976
- Lead Sponsor
- Osaka University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Cases with other retinal disorder such as diabetic retinopathy or macular diseases. Cases with other serious eye diseases such as glaucoma. Cases with previous treatments such as steroid therapy, anti-VEGF therapy or laser photocoagulation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Visual acuity, intraocular pressure, slit lamp and fundus examination, and optical coherence tomography before and at 2 days, 2 weeks, 1, 2, 3, 6, 9 and 12 months after injection. Recording any adverse effects.
- Secondary Outcome Measures
Name Time Method Fluorescein angiography for evaluating retinal circulation at 6 and 12 months after injection.